Biotech

Latest Articles

Vaccine and Keytruda combination helpful in squamous cell carcinoma

.Invulnerable gate inhibitors are the superheroes of cancer therapy. Medicines like Bristol Myers Sq...

Cue Biopharma queues up J&ampJ vet as CBO-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our summary of significant leadership hirings, shootings...

Regeneron's Opdualag competitor presents 57% feedback cost

.Regeneron is actually back along with lasting follow-up for its own LAG-3 inhibitor and PD-1 preven...

AstraZeneca messages records on internal opponents to AbbVie, Pfizer ADCs

.AstraZeneca has discussed an early examine the functionality of its internal antibody-drug conjugat...

iTeos- GSK's TIGIT star shows relevant remodeling

.After declaring a period 3 launch based upon beneficial midstage results, iTeos and also GSK are ac...

More collective FDA may increase unusual disease R&ampD: record

.The FDA should be actually extra available and collaborative to let loose a surge in commendations ...

Zenas, MBX, Bicara scalp to Nasdaq in hot time for biotech IPOs

.It is actually an uncommonly busy Friday for biotech IPOs, along with Zenas BioPharma, MBX and also...

Atea's COVID antiviral stops working to stop hospital stays in stage 3

.Atea Pharmaceuticals' antiviral has actually fallen short yet another COVID-19 test, however the bi...

Neurocrine's bid to save mental illness prospect fails

.Neurocrine Biosciences' schizophrenia program pivot has fallen short. The biotech was actually inca...

Sanofi spends $110M upfront for late-stage radioligand therapy

.Sanofi has created an overdue entry to the radioligand party, paying out one hundred thousand europ...

F 2G brings up $100M for second try to receive brand-new antifungal to market

.After F2G's first attempt to acquire a brand-new lesson of antifungal to market was wrecked by the ...

Moderna targets $1.1 B in R&ampD investing slices, drops 5 programs surrounded by profitability pressures

.Moderna has promised to reduce R&ampD investing through $1.1 billion by 2027. The choice to shrink ...

Sanofi's $80M bank on Key dystrophy medication finishes in stage 3 go under

.Simply 4 months after Sanofi wager $80 million in upfront cash on Fulcrum Therapeutics' losmapimod,...

Oncternal equity sinks 60% in the middle of unemployments, trial discontinuations

.Cancer cells provider Oncternal Therapies is folding all its clinical tests and giving up personnel...

Roche is holding out chances that its own injectable weight problems possibility can ultimately show 25% fat loss in late-stage trial

.Roche is holding out chances that its injectable obesity prospect could inevitably show 25% weight ...

Novo Nordisk hails 'exceptional' effective weight loss lead for dual-acting oral drug in very early trial

.Novo Nordisk has lifted the cover on a phase 1 trial of its dental amylin and GLP-1 receptor co-ago...

AbbVie files suit BeiGene over blood cancer cells drug classified information

.Merely a handful of quick full weeks after succeeding an FDA Fast Track tag for its own investigati...

Lilly provides one-two strike along with 2nd tranche of favorable information on weekly insulin prospect

.Not long after a positive information drop for Eli Lilly's efsitora alfa, the Indianapolis-based fi...

BridgeBio cuts genetics therapy spending plan as scientific data disappoint

.BridgeBio Pharma is actually slashing its genetics treatment budget and also drawing back from the ...

GSK relinquishes HSV vaccination wishes after stage 2 fall short, ceding race to Moderna, BioNTech

.GSK's attempt to develop the first injection for genital herpes simplex virus (HSV) has ended in br...